Apogee Secures $1.3B Blackstone Life Sciences Partnership to Advance Late-Stage Immunology Drug Development
- 4 days ago
- 1 min read
San Francisco, CA and Boston, MA, May 27, 2026 (Globe Newswire) -- Apogee Therapeutics has entered a strategic financing collaboration with Blackstone Life Sciences valued at $1.3 billion. The agreement will support Phase 3 development and potential commercialization of its immunology candidate zumilokibart. The funding is intended to accelerate late-stage clinical progress and prepare the program for possible market launch.
Read full article here.






















Comments